靶向HER2的抗体偶联药德曲妥珠单抗诱导的间质性肺病研究进展
Research progress on the pathogenesis of interstitial lung disease induced by Trastuzumab deruxtecan,an antibody-drug conjugate targeting HER2
林清月 1陈伟 1裴昕莲 1邹维 1张妍1
作者信息
- 1. 解放军联勤保障部队第900医院肿瘤科,福建福州 350025
- 折叠
摘要
德曲妥珠单抗(T-DXd)是靶向人表皮生长因子受体2的新一代抗体偶联药物,抗肿瘤作用较强,已获得国内外众多指南推荐.药物相关性间质性肺病(DILD)作为T-DXd的常见不良反应及致死原因之一,是限制其临床应用的重要因素.T-DXd诱导的DILD发病机制尚不明确,主流观点认为可能与药物被非靶点依赖性摄取有关.糖皮质激素是DILD的重要治疗药物,其他替代药物尚缺乏临床有效性证据.本文综述了T-DXd诱导DILD的发病机制研究进展,旨在为DILD的防治研究提供新思路.
Abstract
Trastuzumab deruxtecan(T-DXd)is a new generation of antibody-drug conjugate targeting human epidermal growth factor receptor 2.It has strong antitumor effects and has been recommended by many authoritative guidelines at home and abroad.Drug-induced interstitial lung disease(DILD)is one of the common adverse reactions and causes of death of T-DXd and is an important factor limiting its clinical application.The pathogenesis of DILD induced by T-DXd is still unclear,and the mainstream view holds that it may be related to the non-target-dependent uptake of the drug.Glucocorticoids are an important treatment method for DILD,and other alternative drugs still lack clinical effectiveness evidence.The research progress on the pathogenesis of T-DXd induced DILD was summarized in this review,aiming to provide new ideas for the prevention and treatment of DILD.
关键词
抗体偶联药物/德曲妥珠单抗/药物相关性间质性肺病/发病机制Key words
antibody-drug conjugate/Trastuzumab deruxtecan/drug-induced interstitial lung disease/pathogenesis引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据